Bausch Health Companies Inc.

BHC

CA0717341071

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.63 USD

Average target price

10.33 USD

Spread / Average Target

+19.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	+7.61%	3.16B
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+25.94%	559B
JOHNSON & JOHNSON	-5.84%	356B
MERCK & CO., INC.	+15.75%	320B
ABBVIE INC.	+4.32%	286B
ASTRAZENECA PLC	+4.00%	213B
NOVARTIS AG	+1.92%	207B
ROCHE HOLDING AG	-7.93%	199B
PFIZER, INC.	-10.00%	147B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:01 2024-04-15 pm EDT			5-day change	1st Jan Change
8.63 ^USD	-1.48%		-10.94%	+7.61%

Apr. 12	Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	MT
Apr. 12	RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	MT

Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
Bausch wins US appeal to block Alvogen generic of diarrhea drug	Apr. 11	RE
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	Apr. 11	CI
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	Apr. 08	MT
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Trump eyes $43 million haul from biggest fundraiser yet	Apr. 06	RE
RBC Raises Bausch Health Target to US$12, Maintains Sector Perform, on Upcoming Xifaxan Litigation Ruling	Apr. 05	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	Apr. 05	MT
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for Uceris Aerosol Foam	Apr. 03	MT
Bausch Health Brief: Bausch Health, Canada Inc. Announcing First Public Drug Plan Listings for UCERIS Aerosol Foam	Apr. 03	MT
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults	Apr. 03	CI
Trump can't match Biden's 2024 fundraising, Republican's campaign says	Mar. 28	RE
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting	Mar. 27	MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting	Mar. 27	MT
Toronto healthcare stocks rise in flat market, Canada Goose slides	Mar. 26	RE
Billionaires sought to help fund Trump bond in civil fraud case, sources say	Mar. 25	RE
Trump floats billionaire Paulson as potential Treasury chief, Bloomberg reports	Mar. 13	RE
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor	Mar. 06	MT
Bausch Health Brief: Salix Pharmaceuticals Announcing a Phase 2 Investigator-Initiated Study of RELISTOR (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma	Mar. 06	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma	Mar. 06	CI
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance	Feb. 23	MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating	Feb. 23	MT
TSX closes at 22-month high powered by tech rally	Feb. 22	RE

Bausch Health Companies Inc.

Equities

BHC